Allogene Therapeutics, Inc. Amortization of Intangible Assets
Allogene Therapeutics, Inc. (ALLO) reported Amortization of Intangible Assets of $0 for the 12-month period ending 2022-12-31, per its 10-K/A filed 2024-03-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2024-03-14
- Allogene Therapeutics, Inc. amortization of intangible assets for the quarter ending 2021-12-31 was $0.00.
- Allogene Therapeutics, Inc. amortization of intangible assets for the quarter ending 2021-09-30 was $0.00.
- Allogene Therapeutics, Inc. amortization of intangible assets for the quarter ending 2021-06-30 was $0.00.
- Allogene Therapeutics, Inc. amortization of intangible assets for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Allogene Therapeutics, Inc. amortization of intangible assets for fiscal 2022 was $0.00.
- Allogene Therapeutics, Inc. amortization of intangible assets for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Allogene Therapeutics, Inc. amortization of intangible assets for fiscal 2020 was $151.00K, a 74.96% decline from fiscal 2019.
- Allogene Therapeutics, Inc. amortization of intangible assets for fiscal 2019 was $603.00K, a 33.41% increase from fiscal 2018.
| Period end | Amortization of Intangible Assets 1 month | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K/A · filed 2024-03-14 | ||||
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $0.00 10-K/A · filed 2024-03-14 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $0.00 derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-05 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $0.00 derived: sum of 4 quarters · filed 2024-03-14 | |
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $151.00K 10-K/A · filed 2024-03-14 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $151.00K 10-Q · filed 2021-11-04 | $302.00K derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $151.00K 10-Q · filed 2021-08-04 | $302.00K derived: sum of 3 quarters · filed 2022-02-23 | $453.00K derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-03-31 | $151.00K 10-Q · filed 2021-05-05 | $302.00K derived: sum of 2 quarters · filed 2022-02-23 | $453.00K derived: sum of 3 quarters · filed 2022-02-23 | $603.00K derived: sum of 4 quarters · filed 2022-02-23 | |
| 2019-12-31 | $151.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $302.00K derived: sum of 2 quarters · filed 2022-02-23 | $452.00K derived: sum of 3 quarters · filed 2022-02-23 | $603.00K 10-K · filed 2022-02-23 | |
| 2019-09-30 | $151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $301.00K derived: sum of 2 quarters · filed 2020-11-04 | $452.00K 10-Q · filed 2020-11-04 | $602.00K derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $150.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $301.00K 10-Q · filed 2020-08-05 | $451.00K derived: sum of 3 quarters · filed 2021-02-25 | $602.00K derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $151.00K 10-Q · filed 2020-05-06 | $301.00K derived: sum of 2 quarters · filed 2021-02-25 | $452.00K derived: sum of 3 quarters · filed 2021-02-25 | $603.00K derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $301.00K derived: sum of 2 quarters · filed 2021-02-25 | $452.00K derived: sum of 3 quarters · filed 2021-02-25 | $452.00K 10-K · filed 2021-02-25 | |
| 2018-09-30 | $151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $302.00K derived: sum of 2 quarters · filed 2019-11-05 | $302.00K 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $151.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $151.00K 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |